u 73122  (TargetMol)

Journal: Microbiology Spectrum

Article Title: D-glucose uptake inhibits bovine alphaherpesvirus 1 post-binding cell process entry via inhibition of PLC-γ1 signaling in a glucose transporter 1-independent manner

doi: 10.1128/spectrum.02456-25

Figure Lengend Snippet: The effects of U73122 and glucose on BoAHV-1 entry process. ( A and B ) MDBK ( A ) and A549 ( B ) cells in six-well plates were subjected to glucose depletion via culturing the cells using glucose-free DMEM for 12 h. The cells were infected with BoAHV-1 (MOI = 1) in the presence of either U73122 or D-glucose alone, or in combination, at the designated concentrations, at 37°C for 30 min. After extensive washes, genomic DNA was extracted, and the viral genome bound to the cells was quantitatively evaluated using qPCR. The data shown are the means of three independent experiments with error bars representing the SDs. The significance was evaluated by Student’s t -test (*, P < 0.05; **, P < 0.01).

Article Snippet: Phospholipase C (PLC) inhibitor U73122 (cat# HY-13419) and GLUT1-specific inhibitor BAY-876 (cat# HY-100017) were ordered from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Infection

Journal: Experimental & Molecular Medicine

Article Title: Temporal vascular pattern remodeling mediated by the FHL2/sFRP2 signaling pathway in tenocytes affects tendon repair and regeneration

doi: 10.1038/s12276-025-01574-2

Figure Lengend Snippet: a Cell viability of HUVECs treated with gradient concentrations of sFRP2 protein (CCK8). The 5–10 pM concentration showed the most significant effect. b Cell viability (CCK8) of HUVECs treated with sFRP2 + U73122 (phospholipase C inhibitor) or Ceapin-A7 (selective ATF6α signaling blocker) or Fz7-21 (FZD7 receptor peptide antagonist). c , d Flow cytometry analysis (panel c ) of apoptosis in HUVECs treated with sFRP2 (7 pM) + U73122 (1 μM)/Ceapin-A7 (30 μM)/Fz7-21 (30 μM), with the percentage of cells exhibiting early apoptosis (LR) and late apoptosis (UR); the relevant statistical results displayed in panel d . e , f Flow cytometry analysis (panel e ) of cell cycle in HUVECs treated with sFRP2 (7 pM) + U73122 (1 μM)/Ceapin-A7 (30 μM)/Fz7-21 (30 μM), with the percentages of cells in the G0/G1, S and G2/M phases; the relevant statistical results displayed in panel f . g , h Scratch wound healing assay (panel g ); %Cell migration rate = (initial width at 0 h − width at specific time point)/initial width at 0 h, *** P < 0.05 versus the sFRP2-treated group; the relevant statistical results displayed in panel h . i – m Tube formation assay (panel i ) with the number of branches (statistical results in panel j ), total branching length (statistical results in panel k ), number of junctions (statistical results in panel l ) and number of meshes (statistical results in panel m ), *** P < 0.05 versus the sFRP2-treated group. n Tenocyte-HUVECs coculture models. o , p WB (panel o ) assessing the expression levels of sFRP2 in tenocytes transfected with siSFRP2 , ** P < 0.05 versus NC, ns: P > 0.05; the relevant statistical results displayed in panel p . q Tube formation assay of HUVECs after coculturing with tenocytes (Calcein-AM staining) (Supplementary Data File ). r The number of branches, total branching length, number of junctions and number of meshes, *** P < 0.05 versus IL-1β-stimulated normal tenocyte-HUVECs coculture group, # P < 0.05 between any two groups.

Article Snippet: Next, HUVECs were divided into the following groups for further assessments: NC group (negative control, untreated), 7 pM-sFRP2 treatment group, 7 pM-sFRP2 + U73122 (1 μM, phospholipase C inhibitor, HY-13419, MedChemExpress) group, 7 pM-sFRP2 + Ceapin-A7 (30 μM, selective ATF6α signaling blocker, HY-108434, MedChemExpress) group and 7 pM-sFRP2 + Fz7-21 (30 μM, FZD7 receptor peptide antagonist, HY-P1454, MedChemExpress) group.

Techniques: Concentration Assay, Flow Cytometry, Wound Healing Assay, Migration, Tube Formation Assay, Expressing, Transfection, Staining